Evolution Research Group Names New COO and CBO


NEW PROVIDENCE, N.J., March 19, 2019 — Evolution Research Group, LLC (ERG), one of the leading, privately held, independent clinical research site companies in the U.S.  with an expertise in early- and late-stage neuroscience drug development, has announced the promotion of Andria Chastain to Chief Operating Officer and the addition of Paul Greene, Ph.D., as Chief Business Officer.

Ms. Chastain has over 20 years of experience in the clinical research industry and has been with ERG since its inception. As COO, she will continue to manage clinical operations and recruitment activities across ERG’s portfolio of sites, working closely with site directors and principal investigators. She also will continue to be intimately involved with M&A strategy. Ms. Chastain previously served as Senior Vice President at the company.

“I am incredibly fortunate to work with so many dedicated professionals whose expertise, commitment to quality, and passion to discover better patient treatments has made us a leader in the industry. Together we will continue to seek solutions that address unmet medical needs and promote the growth of our organization,” said Ms. Chastain.

Dr. Greene joins ERG after six years at Syneos Health and 25 years in the CRO and pharmaceutical industries. He has led product development teams and key customer relationships with a specific focus on central nervous system (CNS) assets.  A psychologist with post-doctoral training as an Eli Lilly Fellow, he has deep experience across the spectrum of CNS disorders with notable concentration in mood disorders, schizophrenia, and pediatrics. In his new role as CBO, he will lead corporate strategic growth initiatives and relationships, business development, client budgets and contracts, and marketing.

“ERG is at a key juncture in its expansion and the experience and professionalism of its experts position the company perfectly for strong growth,” said Dr. Greene. “Clinical sites are critical to the successful execution of research programs and ERG represents the best in clinical research site quality and delivery. I want to leverage that high-caliber performance for the future of ERG and the well-being of the patients we serve.”

“Andria and Paul are formidable leaders who, together with our medical, operational, compliance, and client management teams, will continue to drive the growth and expansion of the organization, while maintaining the level of service ERG has always delivered for our clients, securing our reputation as a leader in the field,” said ERG’s Chief Executive Officer, Lori Wright.

About Evolution Research Group
Evolution Research Group, LLC is comprised of 12 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites. ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, and hepatic impairment, as well as normal healthy volunteers.

For more information, visit ergclinical.com.

SOURCE Evolution Research Group, LLC

Related Links